Description
All participants will receive maraviroc per the approved local label in combination with an optimized background antiretroviral therapy (OBT) regimen, composed of appropriate antiretroviral drugs prescribed by the enrolling physician according to the local standard of care of HIV infected patients. There will be no protocol-mandated patient visits or laboratory tests in this observational, non-interventional study. Data on participants� vital statuses, continued use of maraviroc, and study endpoints will be obtained through follow-up with the treating physician according to the local HIV/AIDS treatment guidelines and routine medical practice. Participants will be followed for up to 5 years after enrollment in the study.
Eligibility
Inclusion Criteria
- Must be antiretroviral treatment experienced and currently being considered for treatment with maraviroc
- Must have HIV-1 tropism assay as a screening for eligibility
- Age 18 years or older
- Must be able to provide informed consent
- Cannot be pregnant or breastfeeding
- Cannot be already exposed to maraviroc or another small molecule CCR5 inhibitor
